ClinicalTrials.gg
TerminatedNCT06628037Updated Oct 30, 2026

SN514-066b Enzyme in Deep Partial Thickness Burns

A Phase 1/2 interventional study of SN514-066b in Burn Injury, sponsored by SERDA bv. Terminated at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by SERDA bv · Phase 1/2, Interventional, and Treatment

How we know

Why this study was terminated
Administrative reasons not for safety
Updated Oct 30, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
13
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 336 studies in Burns with a site in United States — 40 open to participants now, 51 under way, 5 of them phase 3. Burns · United States.

Enrollment
188th of 272
13 · median 26
Started
2025
with 12 others
Phase 1/2
10 of 336
none open now
Registered
309th of 336
by date

Among the 336 studies in Burns with a site in United States, this one is the 188th largest by enrollment of the 272 interventional ones that give a count, is one of 13 that started in 2025, is one of 10 in phase 1/2, and was the 309th registered.

Burns

906 studies on the registry are indexed under Burns; 165 are open to participants now.

Browse Burns studies →

Open to participants now

40 of the 336 studies in Burns with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 87 Burns studies recruiting now, 38 (44%) set no upper age limit and 38 (44%) stop at 75 or younger; 17 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 336 studies in Burns with a site in United States, or all of them as a file.
02

Study summary

This study will examine the tolerability of a gel formulation of the enzyme SN514 in patients with burns suitable for enzymatic debridement. In a rising dose fashion by sequential cohort, concentrations of 0.1%, 0.2%, 0.4% and 0.8% will be tested. Groups of 3 will undergo daily debridement for up to 7 days. Extent of debridement and adverse signs and symptoms will be recorded daily. Dose escalation will stop if a dose level is found to be intolerable. Dose escalation may accelerate if a tested dose is entirely ineffective. There is no placebo control as all burn wounds require debridement.

Read the detailed description

The design of the study is a sequential rising dose to the maximum tolerated dose, in which each subject will be exposed to only one concentration of the test article. Dose limiting toxicities are defined as "Severe" or CTCAE v5 Grade 3 or higher adverse events. This study in burn patients is designed to apply SN514-066b over 25 cm2 (0.14% TBSA for a 1.73 m2 adult) up to 500 cm2 (2.9%), at sequentially rising concentrations of 0.1%, 0.2%, 0.4% and 0.8% (\< 1.0 mg/cm2). The highest exposure would be 0.8% (8 g per 100 cc of gel) over 2.9% of 1.73 m2 = 800 mg or 11.4 mg/kg applied topically (70 kg patient).

03

Conditions studied

  • Burn Injury

Browse trials for

Keywords

  • Maximum tolerated dose
  • Debridement
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  1. Thermal burns caused by fire/flame, scalds or contact
  2. Total burns area available for treatment is 25 to 500 cm2 (a larger area may be burned, but the treatment area must be limited to the stated size, and the treatment area must be exclusive of face, hands, genitalia and sites deemed to be at high risk for developing compartment syndrome)
  3. Target burns for treatment is deep partial thickness (DPT) in depth

Main Exclusion Criteria:

  1. Subject has another life threatening traumatic injury
  2. Patient's proposed study wound site has any of the following conditions:

    • Electrical or chemical etiology
    • Pre-enrollment escharotomy
    • Area is devoid of circulation
    • Located on the face, perineum or genitalia
    • Clinical evidence of wound infection
  3. Poorly controlled diabetes mellitus ( >12%)
  4. greater than 40 kg/m2
  5. Cardio-pulmonary disease (MI within 6 months prior to injury, severe or unstable ischemic heart disease, severe or unstable heart failure, severe pulmonary hypertension, severe or pre-existing oxygen-dependent pulmonary diseases, severe broncho-pneumonia within 1 month prior to injury, dependent asthma, or uncontrolled asthma)
  6. Pre-existing diseases which interfere with circulation (severe peripheral vascular disease, severe circulatory edema and/or lymphedema, regional lymph nodes dissection, significant varicose veins)
  7. Any conditions that would preclude safe treatment or adding further risk to the basic acute burn trauma (such as severe immuno-compromising diseases, life threatening trauma, severe pre-existing coagulation disorder, severe cardiovascular disorder, significant pulmonary disorder, significant liver disorder including post alcoholic abuse impaired function or neoplastic disease, blast injury)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    1st cohort

    Testing 0.10% SN514-066b gel

    Biological: SN514-066b

  • Experimental
    2nd cohort

    Testing 0.20% gel

    Biological: SN514-066b

  • Experimental
    3rd cohort

    Testing 0.40% gel

    Biological: SN514-066b

  • Experimental
    4th cohort

    Testing 0.80% gel

    Biological: SN514-066b

Interventions

  • BiologicalSN514-066b

    Enzyme debrider

06

What researchers measure

Primary outcomes

  1. Determine the maximum tolerated concentration of SN514 gel when applied topically to deep partial thickness burn wounds

    Number of participants with treatment-related adverse events of Grade 3 or higher as assessed using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0, where a higher grade on the scale of 1 to 5 is a worse outcome.

    Time frame: Daily x 7days

Secondary outcomes

  1. Evaluate the time course and extent of debridement when applied daily for up to 7 days

    Percent of eschar removed following each 24 hr debridement

    Time frame: Daily x 7days

  2. Evaluate effects of treatment on inflammation

    Changes from baseline to end of treatment in blood levels of C-reactive protein (CRP) in mg/dL, serum tryptase in ng/mL, and total complement activity (CH50) level in hemolytic units.

    Time frame: Daily x 7days

  3. Observe the incidence of wound erythema

    Record daily the appearance of new, spreading or darkening redness of the treated or adjacent tissue

    Time frame: Daily x 7days

  4. Incidence of wound purulence

    Observe daily for the appearance of purulent material in the treatment area

    Time frame: Daily for 7 days

07

Study locations

1 site
  • USAISR Burn Center
    San Antonio, Texas 78234, United States
08

References and documents

Individual participant data

Plan to share: Undecided — This is a single center trial. If a subsequent burn study is conducted, then certain data may be shared with future investigators. All data are submitted to the IND.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from May 2025 to primary completion in Sep 2026, 15 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Dec 2026 → Sep 2026 and completion May 2027 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2024
First posted
Oct 4, 2024
StartActual
May 8, 2025
Primary completionActual
Sep 2, 2026was Dec 2026
CompletionActual
Sep 2, 2026was May 2027
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Suspended→Terminated Administrative reasons not for safety
changed Oct 30, 2026
Primary completion
Dec 2026→Sep 2, 2026 (actual)
Oct 30, 2026
Study completion
May 2027→Sep 2, 2026 (actual)
Oct 30, 2026
Enrollment
27 (estimated)→13 (actual)
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Suspended→Terminated
    Why stopped Administrative reasons not for safety
    Primary completion Dec 2026→Sep 2, 2026 (now actual)
    Study completion May 2027→Sep 2, 2026 (now actual)
    Enrollment 27 (estimated)→13 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06628037
Lead sponsor
SERDA bv
Collaborators
The Metis Foundation
Responsible party
Sponsor
First posted
Oct 4, 2024
Start date
May 8, 2025
Primary completion
Sep 2, 2026
Completion
Sep 2, 2026
Last update
Oct 30, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion